University Hospital Aachen-ko ikertzaileekin lankidetzan egindako argitalpenak (84)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

2023

  1. Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice

    Cell Death and Disease, Vol. 14, Núm. 8

  2. JNKs protect from cholestatic liver disease progression by modulating Apelin signalling

    JHEP Reports, Vol. 5, Núm. 11

  3. Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

  4. Mouse Models for Hepatic Stellate Cell Activation and Liver Fibrosis Initiation

    Methods in molecular biology (Clifton, N.J.), Vol. 2669, pp. 177-191

  5. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  6. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis

    Gastroenterologia y Hepatologia

  7. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

    Cancers, Vol. 14, Núm. 1

  2. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  3. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  4. Hepatocyte-Directed Delivery of Lipid-Encapsulated Small Interfering RNA

    Methods in molecular biology (Clifton, N.J.), Vol. 2544, pp. 95-106

  5. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  6. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Abnormal liver function test in patients infected with coronavirus (Sars-cov-2): A retrospective single-center study from spain

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-18

  2. An Experimental DUAL Model of Advanced Liver Damage

    Hepatology Communications, Vol. 5, Núm. 6, pp. 1051-1068

  3. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  4. Fat: Quality, or quantity? what matters most for the progression of metabolic associated fatty liver disease (mafld)

    Biomedicines, Vol. 9, Núm. 10

  5. Fibrotic events in the progression of cholestatic liver disease

    Cells, Vol. 10, Núm. 5